Ftse Mib
33.167,64
0,00%
DAX
19.304,88
0,00%
S&P 500
6.021,63
0,57%
NASDAQ
19.175,58
0,63%
Bitcoin
93.507,92
1,67%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Terns Pharmaceuticals Inc (TERN) Terns Pharmaceuticals Inc (TERN) Notizie

Terns Pharmaceuticals Inc

TERN
5,88
0,09 (1,55%)
27 Nov 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
18/11/202422:15EDGAR2Form 8-K - Current report
18/11/202422:05GLOBETerns Pharmaceuticals Appoints Heather Turner, J.D., to..
12/11/202423:06EDGAR2Form S-8 - Securities to be offered to employees in employee..
12/11/202422:45EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/11/202422:15EDGAR2Form 8-K - Current report
12/11/202422:05GLOBETerns Pharmaceuticals Reports Third Quarter 2024 Financial..
06/11/202422:05GLOBETerns Pharmaceuticals to Participate in Upcoming November..
24/10/202420:02EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
07/10/202422:05GLOBETerns Pharmaceuticals Reports Inducement Grant to New..
13/9/202401:00GLOBETerns Announces Closing of Public Offering of Shares of..
12/9/202412:01EDGAR2Form 8-K - Current report
11/9/202422:09EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
11/9/202404:50GLOBETerns Announces Pricing of Upsized $150.15 Million Public..
09/9/202422:40EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
09/9/202422:01GLOBETerns Announces Proposed Public Offering
09/9/202413:16EDGAR2Form 8-K - Current report
09/9/202413:05GLOBETerns Pharmaceuticals Announces Positive Phase 1 Clinical..
05/8/202423:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
05/8/202422:15EDGAR2Form 8-K - Current report
05/8/202422:05GLOBETerns Pharmaceuticals Reports Second Quarter 2024 Financial..
01/8/202422:05GLOBETerns Pharmaceuticals Reports Inducement Grant to New..
29/7/202422:10EDGAR2Form 8-K - Current report
29/7/202422:05GLOBETerns Pharmaceuticals Appoints Biotech Executive Elona Kogan..
22/6/202400:30GLOBETerns Pharmaceuticals Highlights New Preclinical Data..
15/6/202400:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/6/202422:15EDGAR2Form 8-K - Current report
03/6/202422:10GLOBETerns Pharmaceuticals Reports Inducement Grants to New..
30/5/202414:05GLOBETerns Pharmaceuticals to Participate in Upcoming June..
17/5/202422:05GLOBETerns Pharmaceuticals to Participate in UBS Obesity..
13/5/202422:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/5/202414:07EDGAR2Form 8-K - Current report
13/5/202414:05GLOBETerns Pharmaceuticals Reports First Quarter 2024 Financial..
08/5/202422:05GLOBETerns Pharmaceuticals Announces Leadership Changes
07/5/202422:05GLOBETerns Pharmaceuticals to Participate in The Citizens JMP..
03/5/202422:05GLOBETerns Pharmaceuticals Reports Inducement Grant to New..
29/4/202422:05GLOBETerns Pharmaceuticals Announces Data from Ongoing Phase 1..
10/4/202422:05GLOBETerns Pharmaceuticals Appoints Melita Sun Jung as Chief..
14/3/202421:05GLOBETerns Pharmaceuticals Reports Fourth Quarter and Full Year..
11/3/202421:05GLOBETerns Pharmaceuticals Announces Orphan Drug Designation..
07/3/202422:05GLOBETerns Pharmaceuticals Reports Inducement Grant to New..
06/3/202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202422:05GLOBETerns Pharmaceuticals to Participate in Upcoming March..
14/2/202414:57EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07/2/202422:20EDGAR2Form 8-K - Current report
07/2/202422:05GLOBETerns Pharmaceuticals Reports Inducement Grants to New Chief..
07/2/202414:05GLOBETerns Pharmaceuticals Appoints Amy Burroughs as Chief..
02/2/202422:05GLOBETerns Pharmaceuticals Reports Inducement Grant to New..
26/1/202401:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:05GLOBETerns Pharmaceuticals to Highlight 2024 Priorities and..
03/1/202422:05GLOBETerns Pharmaceuticals Reports Inducement Grant to New..
Apertura: 5,85 Min: 5,74 Max: 6,03
Chiusura: 5,79

La tua Cronologia

NASDAQ
TERN
Terns Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network